A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...
University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect ...
The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...
The inverted ILM flap technique yields better macular hole closure than ILM peeling for some high myopic macular holes.
University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...
Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO ...
A wireless implant helped patients with severe macular degeneration regain usable vision. The results point toward a new ...
The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...
No changes in protocol recommended for LUGANO and LUCIA clinical trials –– Masked safety data continues to show no safety signals, consistent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback